ArisGen’s proprietary platforms include:

•        Ariscrown, a unique formulation technology allowing oral administration of peptides and proteins, with managed release profiles

•        Aristarget, a novel platform to modify drug properties and allow their penetration into target compartments, allowing exposure to intra-cellular or CNS targets

These two platforms, used independently or synergistically, open new avenues to treatment success.

ArisGen works with leading biopharma companies to reach the full therapeutic potential of their drugs.

ArisGen also leverages its technology to develop modified peptides to serve unmet medical needs.